How does the presence of MMR deficiency affect your decision to treat with 3 versus 6 months of adjuvant chemotherapy in high risk stage III colon cancer?

Topics: Gastrointestinal Cancers • Medical Oncology

Does your decision for 3 vs 6 months of treatment change for low risk stage III colon cancer?

Answer from: Medical Oncologist at Academic Institution

For stage III dMMR colon cancer patients, oxaliplatin-based adjuvant chemotherapy should be offered as standard of care based on meta-analysis and fluoropyrimidine-only adjuvant chemotherapy is not beneficial (Jin and Sinicrope, PMID 33467526. Cohen et al., PMID 33356421). For high risk stage I...

Related Questions